High-dose-rate surface brachytherapy as a treatment option for renal cell carcinoma cutaneous metastases

CONCLUSIONS: HDR sBT can be a valuable treatment option for cutaneous metastatic renal cell carcinoma, especially for patients with significant comorbidities. The treatment provided was associated with low toxicity and excellent clinical outcome.PMID:34122574 | PMC:PMC8170516 | DOI:10.5114/jcb.2021.105947

Source: Journal of Contemporary Brachytherapy - June 14, 2021 Category: Cancer & Oncology Authors: Łukasz Raszewski Artur J Chyrek Magdalena Marciniak Wojciech M Burchardt Grzegorz M Biele da Adam Chiche ł Source Type: research